Agree with most of your comment. The USA sales team should be in business now. Nothing they like better than a good product and they will have 3 or 4 such products soon to sell. I would like to see progress in Europe with the sales and regulatory approvals. We need to get VasCucel into that ageing market.
We need to outsource the vaccine /immunotherapy business , take a down payment and enjoy the future royalties. Does WP have skin in the game as you alluded to?
Lets actually take a closer look, page-39
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.30 |
Change
0.150(0.99%) |
Mkt cap ! $294.1M | |||
| Open | High | Low | Value | Volume |
| $15.35 | $15.35 | $15.00 | $92.29K | 6.09K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50 | $15.20 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.30 | 276 | 1 |
View Market Depth
| Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |